Toremifene for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia: Results of a Double-Blind, Placebo Controlled, Phase IIB Clinical Trial

2006171 citationsJournal Article

Authors

David T. Price · Regional Urology

Barry Stein · Providence College

Paul Sieber · Urology Associates

Ronald Tutrone · Chesapeake Urology Associates

James L. Bailen

Erik T. Goluboff · Columbia University

Daniel Burzon · Urology Associates

Abstract

Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Estrogen and related hormone effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Urology

Volume 176, Issue 3, pp. 965-971

DOI: 10.1016/j.juro.2006.04.011

Field-Weighted Citation Impact: 13.89